Journal

Biofabrication
ISSN: 1758-5090
Titre abrégé: Biofabrication
Pays: England
ID NLM: 101521964

Informations de publication

Date de publication:
07 04 2021
Historique:
received: 09 12 2020
accepted: 12 01 2021
pubmed: 13 1 2021
medline: 27 10 2021
entrez: 12 1 2021
Statut: epublish

Résumé

Extracellular vesicles (EVs) have become a key tool in the biotechnological landscape due to their well-documented ability to mediate intercellular communication. This feature has been explored and is under constant investigation by researchers, who have demonstrated the important role of EVs in several research fields ranging from oncology to immunology and diagnostics to regenerative medicine. Unfortunately, there are still some limitations to overcome before clinical application, including the inability to confine the EVs to strategically defined sites of interest to avoid side effects. In this study, for the first time, EV application is supported by 3D bioprinting technology to develop a new strategy for applying the angiogenic cargo of human umbilical vein endothelial cell-derived EVs in regenerative medicine. EVs, derived from human endothelial cells and grown under different stressed conditions, were collected and used as bioadditives for the formulation of advanced bioinks. After

Identifiants

pubmed: 33434889
doi: 10.1088/1758-5090/abdacf
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Creative Commons Attribution license.

Auteurs

Fabio Maiullari (F)

Gemelli Molise SpA, Campobasso, Italy.
Istituto Nazionale Genetica Molecolare INGM 'Romeo ed Enrica Invernizzi', Milan, Italy.

Maila Chirivì (M)

Istituto Nazionale Genetica Molecolare INGM 'Romeo ed Enrica Invernizzi', Milan, Italy.
Institute of Biochemistry and Cell Biology, National Research Council of Italy (IBBC-CNR), Monterotondo, Rome, Italy.

Marco Costantini (M)

Institute of Physical Chemistry, Polish Academy of Sciences, Warsaw, Poland.

Anna Maria Ferretti (AM)

Institute of Chemical Sciences and Technologies "Giulio Natta", National Research Council of Italy (SCITEC-CNR), Milano, Italy.

Sandro Recchia (S)

Department of Science and High Technology, University of Insubria, Como, Italy.

Silvia Maiullari (S)

Institute of Biochemistry and Cell Biology, National Research Council of Italy (IBBC-CNR), Monterotondo, Rome, Italy.
Institute of Pathology, Università Cattolica del Sacro Cuore, Rome, Italy.

Marika Milan (M)

Istituto Nazionale Genetica Molecolare INGM 'Romeo ed Enrica Invernizzi', Milan, Italy.
Institute of Biochemistry and Cell Biology, National Research Council of Italy (IBBC-CNR), Monterotondo, Rome, Italy.

Dario Presutti (D)

Institute of Biochemistry and Cell Biology, National Research Council of Italy (IBBC-CNR), Monterotondo, Rome, Italy.
Institute of Physical Chemistry, Polish Academy of Sciences, Warsaw, Poland.

Valentina Pace (V)

Institute of Biochemistry and Cell Biology, National Research Council of Italy (IBBC-CNR), Monterotondo, Rome, Italy.
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Marcello Raspa (M)

Institute of Biochemistry and Cell Biology, National Research Council of Italy (IBBC-CNR), Monterotondo, Rome, Italy.

Ferdinando Scavizzi (F)

Institute of Biochemistry and Cell Biology, National Research Council of Italy (IBBC-CNR), Monterotondo, Rome, Italy.

Massimo Massetti (M)

Department of Cardiovascular Disease, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.

Lella Petrella (L)

Laboratory of Molecular Oncology, Gemelli Molise SpA, Campobasso, Italy.

Mara Fanelli (M)

Laboratory of Molecular Oncology, Gemelli Molise SpA, Campobasso, Italy.

Marta Rizzi (M)

Ufficio Programmazione e Grant Office, National Research Council of Italy (UPGO-CNR), Rome, Italy.

Orazio Fortunato (O)

Tumor Genomics Unit, Department of Research, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy.

Fabiola Moretti (F)

Institute of Biochemistry and Cell Biology, National Research Council of Italy (IBBC-CNR), Monterotondo, Rome, Italy.
IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Eugenio Caradonna (E)

Research Unit, Gemelli Molise SpA, Campobasso, Italy.

Claudia Bearzi (C)

Istituto Nazionale Genetica Molecolare INGM 'Romeo ed Enrica Invernizzi', Milan, Italy.
Institute of Biochemistry and Cell Biology, National Research Council of Italy (IBBC-CNR), Monterotondo, Rome, Italy.

Roberto Rizzi (R)

Istituto Nazionale Genetica Molecolare INGM 'Romeo ed Enrica Invernizzi', Milan, Italy.
Institute of Biomedical Technologies, National Research Council of Italy (ITB-CNR), Segrate, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH